Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Role of N6‐methyladenosine RNA modification in the imbalanced inflammatory homeostasis of arsenic‐induced skin lesions
This study aimed to investigate the effect of N6‐methyladenosine (m6A) modification in modulating inflammatory homeostasis of arsenic (As)‐induced skin lesions. Our bioinformatic analysis revealed abnormal expression of m6A RNA methylation regulators and cytokines in the arsenic‐exposed population. In human keratinocytes, arsenite increased the levels of m6A methylation by upregulating the RNA methyltransferase like 3 (METTL3), mediating the disordered secretion of indicators that reflect inflammatory homeostasis (IL‐6, IL‐17, and IL‐10). The indicators reflecting arsenic‐induced skin lesions (Krt1 and Krt10) were also significantly elevated, which contributed to the occurrence of skin lesions. Our results also confirmed the association between METTL3 with inflammatory homeostasis and arsenic‐induced skin lesions using arsenic‐exposed human skin samples. In the arsenic‐exposed group, the upregulation of METTL3 exacerbated the increase in cytokine levels (IL‐6, IL‐17, and IL‐10), which was associated with the upregulation of keratins (Krt1 and Krt10). In addition, significant correlations among these factors corroborate the theoretical links. Finally, alteration of the m6A levels via knockdown or enhancement of the METTL3 protein could antagonize or aggravate arsenite‐induced imbalanced inflammatory homeostasis and human keratinocyte damage in HaCaT cells. Collectively, our study reveals some evidence that regulation of m6A modification plays an important role in arsenic‐induced skin lesions, which provide a new perspective on the mechanism of arsenite‐induced imbalanced inflammatory homeostasis in the field of RNA epigenetics.
Role of N6‐methyladenosine RNA modification in the imbalanced inflammatory homeostasis of arsenic‐induced skin lesions
This study aimed to investigate the effect of N6‐methyladenosine (m6A) modification in modulating inflammatory homeostasis of arsenic (As)‐induced skin lesions. Our bioinformatic analysis revealed abnormal expression of m6A RNA methylation regulators and cytokines in the arsenic‐exposed population. In human keratinocytes, arsenite increased the levels of m6A methylation by upregulating the RNA methyltransferase like 3 (METTL3), mediating the disordered secretion of indicators that reflect inflammatory homeostasis (IL‐6, IL‐17, and IL‐10). The indicators reflecting arsenic‐induced skin lesions (Krt1 and Krt10) were also significantly elevated, which contributed to the occurrence of skin lesions. Our results also confirmed the association between METTL3 with inflammatory homeostasis and arsenic‐induced skin lesions using arsenic‐exposed human skin samples. In the arsenic‐exposed group, the upregulation of METTL3 exacerbated the increase in cytokine levels (IL‐6, IL‐17, and IL‐10), which was associated with the upregulation of keratins (Krt1 and Krt10). In addition, significant correlations among these factors corroborate the theoretical links. Finally, alteration of the m6A levels via knockdown or enhancement of the METTL3 protein could antagonize or aggravate arsenite‐induced imbalanced inflammatory homeostasis and human keratinocyte damage in HaCaT cells. Collectively, our study reveals some evidence that regulation of m6A modification plays an important role in arsenic‐induced skin lesions, which provide a new perspective on the mechanism of arsenite‐induced imbalanced inflammatory homeostasis in the field of RNA epigenetics.
Role of N6‐methyladenosine RNA modification in the imbalanced inflammatory homeostasis of arsenic‐induced skin lesions
Yang, Fan (Autor:in) / Zhang, Aihua (Autor:in)
Environmental Toxicology ; 37 ; 1831-1839
01.08.2022
9 pages
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
CRISPR/dCas13(Rx) Derived RNA N6‐methyladenosine (m6A) Dynamic Modification in Plant
Wiley | 2024
|CRISPR/dCas13(Rx) Derived RNA N6‐methyladenosine (m6A) Dynamic Modification in Plant
Wiley | 2024
|Wiley | 2025
|